E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Advanced Hepatocellular Carcinoma |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10073071 |
E.1.2 | Term | Hepatocellular carcinoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate the efficacy of orally administered CF102 25 mg twice daily (BID) as compared to placebo, as determined by Overall Survival (OS), when used as second-line therapy in subjects with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B (CPB) cirrhosis |
|
E.2.2 | Secondary objectives of the trial |
- Evaluate other indicators of efficacy of CF102 as compared to placebo, including time to progression (TTP), progression-free survival (PFS), objective response (OR) rate, and disease control (DC) rate in this population; - Explore exposure-response relationships using sparse pharmacokinetic (PK) sampling; - Characterize the safety profile of CF102 in subjects with advanced HCC and CPB cirrhosis; - Characterize the effects of CF102 on laboratory parameters associated with viral hepatitis, hepatic dysfunction, and cirrhosis; and - Explore the relationship between peripheral blood mononuclear cell (WBC) adenosine A3 receptor (A3AR) expression and clinical response
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Pharmacokinetics in selected sites, included in study Protocol Am. 1 dated 16 June 2014
|
|
E.3 | Principal inclusion criteria |
1. Males and females at least 18 years of age. 2. Diagnosis of HCC: • For subjects without underlying cirrhosis at the time of diagnosis, diagnosis of HCC documented by cytology and/or histology. • For subjects with underlying cirrhosis at the time of diagnosis, diagnosis of HCC established according to the American Association for the Study of Liver Diseases Practice Guideline algorithm (Appendix E). 3. HCC is advanced, ie, treatment-refractory or metastatic, and no standard therapies are expected to be curative. 4. Receipt of prior sorafenib therapy for at least 3 weeks and withdrawal from treatment due either to intolerability or to radiographic evidence of disease progression. If treatment was withdrawn due to intolerability manifested as a Grade 3 or 4 event by National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE v4.0), less than 3 weeks of continuous prior administration prior to withdrawal is acceptable (see also Exclusion Criterion #3). 5. Prior sorafenib treatment was discontinued for at least 2 weeks prior to the Baseline Visit. 6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 2 (Appendix B). 7. Cirrhosis classified as Child-Pugh Class B (Appendix C). 8. The following laboratory values must be documented within 3 days prior to the first dose of study drug: • Absolute neutrophil count (ANC) 1.5 × 109/L • Platelet count 75 × 109/L • Serum creatinine 2.0 mg/dL • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × the upper limit of normal (ULN) • Total bilirubin ≤ 3.0 mg/dL • Serum albumin ≥ 2.8 g/dL • Prothrombin time (PT) no greater than 6 seconds longer than control. 9. Life expectancy of ≥ 6 weeks. 10. For women of childbearing potential, negative serum pregnancy test result. 11. Provide written informed consent to participate. 12. Willing to comply with scheduled visits, treatment plans, laboratory assessments, and other trial related procedures.
|
|
E.4 | Principal exclusion criteria |
1. Receipt of no, or of > 1, prior systemic drug therapies for HCC. 2. Receipt of systemic cancer therapy, immunomodulatory drug therapy, immunosuppressive therapy, or corticosteroids > 20 mg/day prednisone or equivalent within 14 days prior to the Baseline Visit or concurrently during the trial. 3. Presence of an acute or chronic toxicity of prior chemotherapy that has not resolved to ≤ Grade 1, as determined by CTCAE v 4.0. 4. Locoregional treatment within 4 weeks prior to the Baseline Visit. 5. Major surgery or radiation therapy within 4 weeks prior to the Baseline Visit. 6. Use of any investigational agent within 4 weeks prior to the Baseline Visit. 7. Child-Pugh Class A or C cirrhosis, or hepatic encephalopathy. 8. Occurrence of esophageal or other gastrointestinal hemorrhage requiring transfusion within 4 weeks prior to the Baseline Visit. 9. Uncontrolled or clinically unstable thyroid disease, per judgement of the Principal Investigator. 10. Active bacterial, viral, or fungal infection requiring systemic therapy or operative or radiological intervention. 11. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness. 12. Liver transplant. 13. Active malignancy other than HCC. 14. Uncontrolled arterial hypertension or congestive heart failure (New York Heart Association Classification 3 or 4) (Appendix B). 15. Angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug. 16. History of or ongoing cardiac dysrhythmias requiring treatment, atrial fibrillation of any grade, or persistent prolongation of the QTc (Fridericia) interval to > 450 msec for males or > 470 msec for females. 17. Pregnant or lactating female. 18. Women of childbearing potential, unless they agree to use dual contraceptive methods which, in the opinion of the Investigator, are effective and adequate for the subject’s circumstances while on study drug. 19. Men who partner with a woman of childbearing potential, unless they agree to use effective, dual contraceptive methods (ie, a condom, with female partner using oral, injectable, or barrier method) while on study drug and for 3 months afterward. 20. Any severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with trial participation or study drug administration; may interfere with the informed consent process and/or with compliance with the requirements of the trial; or may interfere with the interpretation of trial results and, in the Investigator’s opinion, would make the subject inappropriate for entry into this trial.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall Survival, defined as the number of days from first dose to death due to any cause |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Survival status will be assessed continuously |
|
E.5.2 | Secondary end point(s) |
Time To Progression, Progression -free Survival, Overall Response rate (consisting of Complete Response (CR) or Partial Response (PR) in subjects who enter with measurable disease by RECIST v1.1), and Disease Control rate which includes subjects with Overall Response as well as those with Stable Disease (SD) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Tumor status will be assessed at baseline and every 8 weeks thereafter (i.e., at the end of even-numbered cycles) by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST v1.1 criteria as modified by Santoro [2013].
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Bulgaria |
Israel |
Romania |
Serbia |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The post-accrual treatment period will continue until a total of 75 subjects have died |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |